Department of Neurosurgery, Kocaeli University, School of Medicine, Kocaeli, Turkey.
J Neurosurg. 2010 Jan;112(1):99-107. doi: 10.3171/2009.4.JNS09182.
In this report, the authors describe their experience with surgical access to the cavernous sinus via a fully transnasal endoscopic approach in 20 cases. Clinical and endocrinological follow-up are discussed.
The authors used an endoscopic transsphenoidal approach in 192 patients with pituitary adenomas between September 1997 and January 2008, adding a cavernous sinus approach in 20 patients with invasive tumors during the last 5 years of this period [corrected]. Parasellar extension of the tumor was measured according to the Knosp Scale. Radical tumor removal was achieved in 13 (65%) of 20 patients, and subtotal removal in 7 (35%). The authors used recently defined cavernous sinus approaches in the first 14 cases, including the paraseptal approach in 6, middle turbinectomy in 7, and contralateral middle turbinectomy in 1 case. Combined approaches rather than defined standard cavernous sinus approaches were used in 4 cases and an extended approach in 2.
The tumors included nonsecretory adenomas in 5 cases (25%), growth hormone-secreting adenomas in 7 (35%), prolactin-secreting adenomas in 4 (20%), and adrenocorticotropic hormone-secreting adenomas in 4 cases (20%). Normal growth hormone and insulin-like growth factor 1 levels were achieved in 4 patients (57%) with growth hormone adenomas, and remission criteria were obtained in 3 patients with prolactinomas and 3 patients with adrenocorticotropic hormone-secreting adenomas.
Compared with transcranial and microscopic transsphenoidal surgery, endoscopic transsphenoidal surgery offers a wide exposure for cavernous sinus medial wall adenomas that enables removal of the adenoma from the medial cavernous sinus wall. Because of the necessity for multidisciplinary treatment to achieve satisfactory results, Gamma Knife surgery and medical therapy should be supplementary treatment options after endoscopic transsphenoidal surgery.
本报告作者描述了他们在 20 例病例中通过完全经鼻内镜入路对海绵窦进行手术入路的经验。讨论了临床和内分泌随访情况。
作者在 1997 年 9 月至 2008 年 1 月期间使用内镜经蝶窦入路治疗了 192 例垂体腺瘤患者,并在该期间的最后 5 年中对 20 例侵袭性肿瘤患者增加了海绵窦入路。根据 Knosp 量表测量肿瘤的鞍旁扩展。20 例患者中 13 例(65%)实现了肿瘤的根治性切除,7 例(35%)实现了次全切除。作者在最初的 14 例中使用了最近定义的海绵窦入路,包括 6 例副间隔入路、7 例中鼻甲切除术和 1 例对侧中鼻甲切除术。4 例采用了联合入路,而非标准的海绵窦入路,2 例采用了扩展入路。
肿瘤包括 5 例(25%)无分泌功能腺瘤、7 例(35%)生长激素分泌腺瘤、4 例(20%)催乳素分泌腺瘤和 4 例(20%)促肾上腺皮质激素分泌腺瘤。4 例生长激素腺瘤患者的生长激素和胰岛素样生长因子 1 水平恢复正常,3 例催乳素瘤患者和 3 例促肾上腺皮质激素腺瘤患者达到缓解标准。
与经颅和显微镜经蝶窦手术相比,内镜经蝶窦手术为海绵窦内侧壁腺瘤提供了广泛的暴露,使腺瘤从内侧海绵窦壁切除。由于需要多学科治疗才能获得满意的结果,伽玛刀手术和药物治疗应作为内镜经蝶窦手术后的补充治疗选择。